Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1734741

registered interest
date	16/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Psychiatric Hospitals: Autism
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will have discussions with (a) the National Autistic Society and (b) other autism charities on (i) mental health reform and (ii) the detention of autistic people in mental health hospitals.
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	9544
answer	answer is ministerial correction date of answer 24/10/2024 answer text <p>On 17 July 2024, the King’s Speech set out the Government’s commitment to modernise the Mental Health Act. Department officials are now working to prepare the Mental Health Bill for introduction when parliamentary time allows.</p><p>As part of the Department’s preparations, plans are underway for stakeholder engagement once the bill is introduced. This will involve engaging with autism charities, including the National Autistic Society, on a range of related issues.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 24/10/2024 14:30:50 answering member 4359 label Biography information for Stephen Kinnock
tabling member	4673 label Biography information for Jo Platt

1734742

registered interest
date	16/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Psychiatric Hospitals: Autism
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Dynamic Support Register in preventing autistic people from being detained in mental health hospitals.
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	9545
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>NHS England published updated policy and guidance on Dynamic Support Registers (DSRs) and Care (Education) and Treatment Reviews (C(E)TRs) on 25 January 2023, for implementation from 1 May 2023. The purpose of the updated policy and guidance is to help ensure that people with a learning disability and autistic people get the right support in their communities, and to prevent hospital admission.</p><p>NHS England produced the updated policy and guidance following a process of reviewing the learning since the inception of DSRs and C(E)TRs, including consultation and engagement with people with lived experience. This process included drawing on the findings of the Norfolk Safeguarding Adults Board’s review of the deaths of Joanna, Jon, and Ben at Cawston Park in Norfolk and the subsequent safe and wellbeing reviews for all people with a learning disability and autistic people in mental health hospitals, to ensure they are an effective provision.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 30/10/2024 10:26:20 answering member 4359 label Biography information for Stephen Kinnock
tabling member	4673 label Biography information for Jo Platt

1734743

registered interest
date	16/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Autism: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to support Integrated Care Boards to ensure appropriate provision of autism (a) assessment and (b) support services.
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	9546
answer	answer is ministerial correction date of answer 30/10/2024 answer text <p>The Department is currently considering next steps to improve diagnostic assessment and support for autistic people. It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including autism assessment and support services, in line with National Institute for Health and Care Excellence guidelines.</p><p>On 5 April 2023, NHS England published a national framework and operational guidance to deliver improved outcomes in all-age autism assessment pathways. This guidance will help ICBs and the National Health Service to deliver improved outcomes for children, young people, and adults referred to an autism assessment service. The guidance also sets out what support should be available before an assessment, and what support should follow a recent diagnosis of autism based on the available evidence. In 2024/25, £4.3 million is available nationally to improve services for autistic children and young people, including autism assessment services.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 30/10/2024 10:46:42 answering member 4359 label Biography information for Stephen Kinnock
tabling member	4673 label Biography information for Jo Platt

1734404

registered interest
date	15/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methylphenidate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has had round tables with suppliers of methylphenidate prolonged-release tablets since April 2024; what discussions his Department has had on the difficulties suppliers are facing; and what steps his Department is taking to help ensure (a) patients and (b) health care providers have reasonable expectations of supply.
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	9215
answer	answer is ministerial correction date of answer 22/10/2024 answer text <p>The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.</p><p>We are continuing to work to resolve supply issues, where they remain, for methylphenidate prolonged-release tablets. Although no further roundtables have been held since April 2024, we have continued extensive engagement with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024 onwards.</p><p>In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinions for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.</p><p>To aid ADHD service providers and prescribers further we have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 22/10/2024 12:32:22 answering member 4444 label Biography information for Karin Smyth
tabling member	4673 label Biography information for Jo Platt

1732043

registered interest
date	07/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help people who are unable to access the ADHD medication they need.
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	7531
answer	answer is ministerial correction date of answer 11/10/2024 answer text <p>The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level.</p><p>The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.</p><p>We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024.</p><p>In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.</p><p>To aid ADHD service providers and prescribers further we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 7532 7533 question first answered 11/10/2024 08:39:25 answering member 4444 label Biography information for Karin Smyth
tabling member	4673 label Biography information for Jo Platt

1732044

registered interest
date	07/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to coordinate a local plan with (a) NHS Trusts and (b) healthcare organisations to help tackle shortages of ADHD medication .
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	7532
answer	answer is ministerial correction date of answer 11/10/2024 answer text <p>The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level.</p><p>The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.</p><p>We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024.</p><p>In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.</p><p>To aid ADHD service providers and prescribers further we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 7531 7533 question first answered 11/10/2024 08:39:25 answering member 4444 label Biography information for Karin Smyth
tabling member	4673 label Biography information for Jo Platt

1732045

registered interest
date	07/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department is making with manufacturers on resolving issues of ADHD medicine supply.
tabling member constituency	Leigh and Atherton
tabling member printed	Jo Platt
uin	7533
answer	answer is ministerial correction date of answer 11/10/2024 answer text <p>The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level.</p><p>The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.</p><p>We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024.</p><p>In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.</p><p>To aid ADHD service providers and prescribers further we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 7531 7532 question first answered 11/10/2024 08:39:25 answering member 4444 label Biography information for Karin Smyth
tabling member	4673 label Biography information for Jo Platt

1151449

registered interest
date	22/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Visitors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of health visitors in England in each year since 2010.
tabling member constituency	Leigh
tabling member printed	Jo Platt
uin	3796
answer	answer is ministerial correction date of answer 30/10/2019 answer text <p>The data is not available in the format requested.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 30/10/2019 17:46:56 answering member 4380 label Biography information for Jo Churchill
tabling member	4673 label Biography information for Jo Platt

1151451

registered interest
date	22/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Visitors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effect of trends in the level of health visitors in England on children's health.
tabling member constituency	Leigh
tabling member printed	Jo Platt
uin	3797
answer	answer is ministerial correction date of answer 30/10/2019 answer text <p>Health visiting is an essential part of broader early years family support. The number of health visitors employed by National Health Service organisations reported through Electronic Staff Records shows reduction, but this is not a complete picture of the workforce as this goes not include social enterprises, private sector organisations or local authorities. It is the responsibility of local authorities to determine how the programme is provided to their communities based upon local needs.</p><p>Data on mandated health visitor reviews shows national coverage remains above those achieved in 2015. However, there is variation at a local level. Data is available at the following link:</p><p><a href="https://www.gov.uk/government/statistics/health-visitor-service-delivery-metrics-2018-to-2019" target="_blank">https://www.gov.uk/government/statistics/health-visitor-service-delivery-metrics-2018-to-2019</a></p><p>Progress against health and wellbeing outcomes for the zero to five years population, and inequalities in these outcomes, is published in Early Years Profiles at the following link:</p><p><a href="https://fingertips.phe.org.uk/profile/child-health-profiles/data#page/1/gid/1938133223/pat/6/par/E12000001/ati/102/are/E06000005" target="_blank">https://fingertips.phe.org.uk/profile/child-health-profiles/data#page/1/gid/1938133223/pat/6/par/E12000001/ati/102/are/E06000005</a></p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 30/10/2019 17:51:23 answering member 4380 label Biography information for Jo Churchill
tabling member	4673 label Biography information for Jo Platt

1150388

registered interest
date	17/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Contamination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reasons parents and children of people who have died after being infected by contaminated blood products do not receive on-going financial support.
tabling member constituency	Leigh
tabling member printed	Jo Platt
uin	1790
answer	answer is ministerial correction date of answer 24/10/2019 answer text <p>The England Infected Blood Support Scheme (EIBSS) currently makes provision for <em>ex gratia</em> one-off payments to eligible spouses, civil partners and long-term partners for individuals meeting qualifying criteria.</p><p> </p><p>The EIBSS also makes provision to help with the costs of bringing up children of an infected beneficiary in the form of an income top-up payment. This is a discretionary monthly payment to increase household income to help with general living costs. These are means-tested payments for dependants who are defined as children of an infected beneficiary up to the age of 18 years, or up to 21 if in full-time education.</p><p> </p><p>In July 2017 the then Prime Minister announced the establishment of the Infected Blood Enquiry. This statutory inquiry chaired by Sir Brian Langstaff, will examine why men, women and children in the United Kingdom were given infected blood and/or infected blood products and the impact on their families. The Inquiry will consider the nature and the adequacy of the treatment, care and support (including financial assistance) and the Government will carefully consider any recommendations made.</p><p> </p><p> </p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 24/10/2019 15:47:42 answering member 1481 label Biography information for Ms Nadine Dorries
tabling member	4673 label Biography information for Jo Platt